Skip to content
Open access

Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.

Sep 2026 · International Journal of Obesity · 0 citations · 10 references
Medicine

TL;DR

In this indirect treatment comparison for obesity treatment in adults without T2D, with obesity, or overweight with ≥1 ORC, compared with semaglutide, tirzepatide 10 or 15’mg was associated with improvements in weight reduction, body composition and several cardiometabolic risk factors and generally similar safety profiles.

Abstract

BACKGROUND/

Objectives

Tirzepatide is a once-weekly, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) for obesity treatment. This indirect treatment comparison (ITC) assessed the relative efficacy and safety of tirzepatide versus the GLP-1 RA semaglutide. SUBJECTS/

Methods

Adjusted (for sex, and sex and ethnicity) and unadjusted ITCs compared tirzepatide 5, 10, and 15 mg/week and semaglutide 2.4 mg/week via placebo, all adjunct to reduced-calorie diet and increased physical activity, at primary trial endpoints (Week 68, STEP 1; Week 72, SURMOUNT-1) for adults with obesity (BMI ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) with ≥1 obesity-related complication (ORC), without type 2 diabetes (T2D).

Results

For efficacy estimand unadjusted ITCs, tirzepatide 10 and 15 mg demonstrated statistically significant improvements versus semaglutide in weight reduction (-5.10 kg [-6.63, - 3.57], -6.50 kg [-8.03,-4.97]), participants achieving ≥10/15/20% weight reduction, BMI (-1.87 kg/m2 [-2.43,-1.31], -2.37 kg/m2 [-2.93,-1.81]), waist circumference (-5.25 cm [-6.69,-3.81], -5.75 cm [-7.19,-4.31]), HbA1c(-0.08% [-0.13,-0.03], -0.10% [-0.15, -0.05]) and fasting plasma glucose (-1.69 mg/dL [-3.36,-0.02], -2.52 mg/dL [-4.19,-0.85]). Tirzepatide 5 mg showed non-significant trends of greater improvements in these outcomes versus semaglutide. All tirzepatide doses showed statistically significantly greater decreases in diastolic blood pressure (-1.90 mmHg [-3.19,-0.61], -2.40 mmHg [-3.69,-1.11], -1.30 mmHg [-2.59,-0.01]) and increases in HDL (3.80% [1.23,6.37], 5.40% [2.83,7.97], 5.00% [2.43,7.57]). In participants reporting on body composition, tirzepatide 15 mg demonstrated statistically significant improvements in body composition versus semaglutide, with a reduction of percentage body fat mass (-3.50% [-6.66, -0.34]) and an increase of percentage body lean mass (3.40% [0.40, 6.40]). Results were broadly consistent across adjusted and unadjusted comparisons. Safety profiles of tirzepatide and semaglutide were generally similar.

Conclusions

In this ITC for obesity treatment in adults without T2D, with obesity, or overweight with ≥1 ORC, compared with semaglutide, tirzepatide 10 or 15 mg was associated with improvements in weight reduction, body composition and several cardiometabolic risk factors and generally similar safety profiles.

Read PDF

Similar papers

Review Open access Oct 2026

Tirzepatide and Semaglutide in Type 2 Diabetes Mellitus and Obesity: A Comparative Assessment of Efficacy and Safety (Review)

INTRODUCTION. In the last two decades, pharmacotherapy for obesity and type 2 diabetes mellitus has evolved toward drugs that target the incretin system, such as semaglutide, a glucagon-like peptide-1 (GLP-1) receptoragonist, and tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 recept...

E. M. Eliseeva, A. A. Druzhinina, A. A. Chistokhina · 0 citations
Open access Oct 2026

Efficacy and safety of once-weekly Semaglutide for weight management in adults with overweight or obesity with or without type 2 diabetes: A real-world clinical trial in Bangladesh

Introduction: Semaglutide has shown substantial weight reduction in trials, but real-world evidence from South Asian populations is scarce. We evaluated the efficacy and safety of once-weekly semaglutide 2·4 mg over 26 weeks in adults with overweight or obesity, with and without type 2 diabetes mellitus (T2DM). Methods...

Q. T. Islam · 0 citations
Open access Oct 2026

Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran

Although tirzepatide provided greater health benefits, its higher cost limited its cost-effectiveness at current prices, and semaglutide was the cost-effective injectable GLP-1-1-based therapy in Iran.

Negin Reiszadeh, R. Radmanesh, R. Heshmat et al. · 0 citations
Open access Aug 2026

Efficacy and safety of semaglutide and tirzepatide in the therapy of obesity and type 2 diabetes – current state of knowledge

Background. The diabesity epidemic (obesity and type 2 diabetes) requires a shift from a glucocentric to a holistic approach, making weight reduction a clinical goal equal to glycemic control. Incretin-based therapies (semaglutide, tirzepatide) represent a breakthrough due to their pleiotropic effects.   Aim. This st...

J. Chyl, Ł. Kowalewski, O. Gutowska et al. · 0 citations
Aug 2026

Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.

BACKGROUND Therapies targeting GLP-1 or glucose-dependent insulinotropic polypeptide (GIP) receptors have provided efficacious weight reduction in adults with obesity. Mazdutide, a glucagon and GLP-1 receptor dual agonist, presents a novel opportunity for differentiated weight reduction. We aimed to evaluate the effica...

Stanley H. Hsia, H. Bays, Liana K. Billings et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.